{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T23:47:35Z","timestamp":1782863255595,"version":"3.54.5"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"crossref","award":["5\/13\/16\/2022\/NCD-III\/ 138204"],"award-info":[{"award-number":["5\/13\/16\/2022\/NCD-III\/ 138204"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-026-03299-2","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T06:01:14Z","timestamp":1780466474000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["P38MAPK targeting in pancreatic ductal adenocarcinoma: Promising interventional approach for breaking drug resistance and tumor control"],"prefix":"10.1007","volume":"43","author":[{"given":"Vandana","family":"Mehra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khushi","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Freixinos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prasenjit","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nihar Ranjan","family":"Dash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gayatri","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0861-8713","authenticated-orcid":false,"given":"Monika","family":"Bhardwaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9034-4031","authenticated-orcid":false,"given":"C\u00e9line","family":"Gongora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5269-2481","authenticated-orcid":false,"given":"Hridayesh","family":"Prakash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"issue":"3","key":"3299_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"Cancer J Clin"},{"issue":"4","key":"3299_CR2","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41575-019-0109-y","volume":"16","author":"EA Collisson","year":"2019","unstructured":"Collisson EA, Bailey P, Chang DK, Biankin AV. Molecular subtypes of pancreatic cancer. Nat reviews Gastroenterol Hepatol. 2019;16(4):207\u201320.","journal-title":"Nat reviews Gastroenterol Hepatol"},{"issue":"9","key":"3299_CR3","doi-asserted-by":"publisher","first-page":"a031435","DOI":"10.1101\/cshperspect.a031435","volume":"8","author":"AM Waters","year":"2018","unstructured":"Waters AM, Der CJ. KRAS: the critical driver and therapeutic target for pancreatic cancer. Cold Spring Harbor Perspect Med. 2018;8(9):a031435.","journal-title":"Cold Spring Harbor Perspect Med"},{"issue":"8","key":"3299_CR4","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1158\/0008-5472.CAN-23-1200","volume":"84","author":"SP Singh","year":"2024","unstructured":"Singh SP, Dosch AR, Mehra S, De Castro Silva I, Bianchi A, Garrido VT, et al. Tumor cell\u2013intrinsic p38 MAPK signaling promotes IL1\u03b1-mediated stromal inflammation and therapeutic resistance in pancreatic cancer. Cancer Res. 2024;84(8):1320\u201332.","journal-title":"Cancer Res"},{"issue":"3","key":"3299_CR5","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1042\/BJ20100323","volume":"429","author":"A Cuadrado","year":"2010","unstructured":"Cuadrado A, Nebreda AR. Mechanisms and functions of p38 MAPK signalling. Biochem J. 2010;429(3):403\u201317.","journal-title":"Biochem J"},{"issue":"8","key":"3299_CR6","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1016\/j.bbamcr.2007.03.010","volume":"1773","author":"A Cuenda","year":"2007","unstructured":"Cuenda A, Rousseau S. p38 MAP-kinases pathway regulation, function and role in human diseases. Biochim et Biophys Acta (BBA)-Molecular Cell Res. 2007;1773(8):1358\u201375.","journal-title":"Biochim et Biophys Acta (BBA)-Molecular Cell Res"},{"issue":"1","key":"3299_CR7","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1007\/s12325-021-01941-1","volume":"39","author":"J Gao","year":"2022","unstructured":"Gao J, Zhu L, Zhuang H, Lin B. Human Epididymis Protein 4 and Lewis y Enhance Chemotherapeutic Resistance in Epithelial Ovarian Cancer Through the p38 MAPK Pathway. Adv Therapy. 2022;39(1):360\u201378.","journal-title":"Adv Therapy"},{"issue":"12","key":"3299_CR8","doi-asserted-by":"publisher","first-page":"9867","DOI":"10.3390\/ijms24129867","volume":"24","author":"EJ Jung","year":"2023","unstructured":"Jung EJ, Kim HJ, Shin SC, Kim GS, Jung J-M, Hong SC, et al. \u03b2-Lapachone exerts Anticancer effects by Downregulating p53, Lys-Acetylated Proteins, TrkA, p38 MAPK, SOD1, Caspase-2, CD44 and NPM in oxaliplatin-resistant HCT116 colorectal Cancer cells. Int J Mol Sci. 2023;24(12):9867.","journal-title":"Int J Mol Sci"},{"issue":"7","key":"3299_CR9","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.4161\/auto.20268","volume":"8","author":"S Paillas","year":"2012","unstructured":"Paillas S, Causse A, Marzi L, De Medina P, Poirot M, Denis V, et al. MAPK14\/p38\u03b1 confers irinotecan resistance to TP53-defective cells by inducing survival autophagy. Autophagy. 2012;8(7):1098\u2013112.","journal-title":"Autophagy"},{"issue":"4","key":"3299_CR10","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/s41419-021-03572-4","volume":"12","author":"M Lepore Signorile","year":"2021","unstructured":"Lepore Signorile M, Grossi V, Di Franco S, Forte G, Disciglio V, Fasano C, et al. Pharmacological targeting of the novel \u03b2-catenin chromatin-associated kinase p38\u03b1 in colorectal cancer stem cell tumorspheres and organoids. Cell Death Dis. 2021;12(4):316.","journal-title":"Cell Death Dis"},{"issue":"5","key":"3299_CR11","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.ccr.2013.09.014","volume":"24","author":"F Klug","year":"2013","unstructured":"Klug F, Prakash H, Huber PE, Seibel T, Bender N, Halama N, et al. Low-dose irradiation programs macrophage differentiation to an iNOS+\/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell. 2013;24(5):589\u2013602.","journal-title":"Cancer Cell"},{"issue":"3","key":"3299_CR12","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1093\/carcin\/bgw007","volume":"37","author":"H Prakash","year":"2016","unstructured":"Prakash H, Klug F, Nadella V, Mazumdar V, Schmitz-Winnenthal H, Umansky L. Low doses of gamma irradiation potentially modifies immunosuppressive tumor microenvironment by retuning tumor-associated macrophages: lesson from insulinoma. Carcinogenesis. 2016;37(3):301\u201313.","journal-title":"Carcinogenesis"},{"issue":"5","key":"3299_CR13","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1158\/1078-0432.CCR-15-1718","volume":"22","author":"A Patnaik","year":"2016","unstructured":"Patnaik A, Haluska P, Tolcher AW, Erlichman C, Papadopoulos KP, Lensing JL, et al. A first-in-human phase I study of the oral p38 MAPK inhibitor, ralimetinib (LY2228820 dimesylate), in patients with advanced cancer. Clin Cancer Res. 2016;22(5):1095\u2013102.","journal-title":"Clin Cancer Res"},{"key":"3299_CR14","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.radonc.2020.09.036","volume":"154","author":"J Biau","year":"2021","unstructured":"Biau J, Thivat E, Chautard E, Stefan D, Boone M, Chauffert B, et al. Phase 1 trial of ralimetinib (LY2228820) with radiotherapy plus concomitant temozolomide in the treatment of newly diagnosed glioblastoma. Radiother Oncol. 2021;154:227\u201334.","journal-title":"Radiother Oncol"},{"key":"3299_CR15","doi-asserted-by":"crossref","unstructured":"Vergote I, Heitz F, Buderath P, Powell MA, Sehouli J, Lee CM, et al. A randomized, double-blind, placebo-controlled phase Ib\/II study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine (G) and carboplatin (C) versus GC for women with recurrent platinum-sensitive ovarian cancer. American Society of Clinical Oncology; 2019.","DOI":"10.1200\/JCO.2019.37.15_suppl.5537"},{"issue":"4","key":"3299_CR16","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.gendis.2021.04.008","volume":"9","author":"M Chen","year":"2022","unstructured":"Chen M, Liu Y, Yang Y, Qiu Y, Wang Z, Li X, Zhang W. Emerging roles of activating transcription factor (ATF) family members in tumourigenesis and immunity: Implications in cancer immunotherapy. Genes Dis. 2022;9(4):981\u201399.","journal-title":"Genes Dis"},{"issue":"4","key":"3299_CR17","doi-asserted-by":"publisher","first-page":"pbad028","DOI":"10.1093\/pcmedi\/pbad028","volume":"6","author":"A Amarah","year":"2023","unstructured":"Amarah A, Elsabagh AA, Ouda A, Karen O, Ferih K, Elmakaty I, Malki MI. Emerging roles of activating transcription factor 2 in the development of breast cancer: a comprehensive review. Precision Clin Med. 2023;6(4):pbad028.","journal-title":"Precision Clin Med"},{"issue":"9","key":"3299_CR18","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1158\/1541-7786.MCR-22-0695","volume":"21","author":"Y Han","year":"2023","unstructured":"Han Y, Katayama S, Futakuchi M, Nakamichi K, Wakabayashi Y, Sakamoto M, et al. Targeting c-Jun is a potential therapy for luminal breast cancer bone metastasis. Mol Cancer Res. 2023;21(9):908\u201321.","journal-title":"Mol Cancer Res"},{"issue":"139","key":"3299_CR19","doi-asserted-by":"publisher","first-page":"ra13982","DOI":"10.1126\/scitranslmed.3003960","volume":"4","author":"H Cai","year":"2012","unstructured":"Cai H, Santiago FS, Prado-Lourenco L, Wang B, Patrikakis M, Davenport MP, et al. DNAzyme targeting c-jun suppresses skin cancer growth. Sci Transl Med. 2012;4(139):ra13982\u201382.","journal-title":"Sci Transl Med"},{"key":"3299_CR20","doi-asserted-by":"publisher","first-page":"1542204","DOI":"10.3389\/fphar.2025.1542204","volume":"16","author":"ZN Nizami","year":"2025","unstructured":"Nizami ZN, Al Azzani M, Khaldi S, Wali AF, Magramane R, Samad SA, et al. Rhus coriaria (Sumac) induces autophagic cell death and inhibits mTOR, p38MAPK and STAT3 pathways in 5fluorouracil-resistant colorectal cancer cells. Front Pharmacol. 2025;16:1542204.","journal-title":"Front Pharmacol"},{"issue":"10","key":"3299_CR21","first-page":"2216","volume":"9","author":"R Chen","year":"2019","unstructured":"Chen R, Qiao Y, Hu W, Cheng Q, Xie H, Zhou L, et al. LY2228820 induces synergistic anti-cancer effects with anti-microtubule chemotherapeutic agents independent of P-glycoprotein in multidrug resistant cancer cells. Am J Cancer Res. 2019;9(10):2216.","journal-title":"Am J Cancer Res"},{"issue":"4","key":"3299_CR22","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.3892\/ijo.2013.1814","volume":"42","author":"JW Antoon","year":"2013","unstructured":"Antoon JW, Nitzchke AM, Martin EC, Rhodes LV, Nam S, Wadsworth S, et al. Inhibition of p38 mitogen-activated protein kinase alters microRNA expression and reverses epithelial-to-mesenchymal transition. Int J Oncol. 2013;42(4):1139\u201350.","journal-title":"Int J Oncol"},{"issue":"5","key":"3299_CR23","doi-asserted-by":"publisher","first-page":"e0267855","DOI":"10.1371\/journal.pone.0267855","volume":"17","author":"S Matou-Nasri","year":"2022","unstructured":"Matou-Nasri S, Najdi M, AlSaud NA, Alhaidan Y, Al-Eidi H, Alatar G, et al. Blockade of p38 MAPK overcomes AML stem cell line KG1a resistance to 5-Fluorouridine and the impact on miRNA profiling. PLoS ONE. 2022;17(5):e0267855.","journal-title":"PLoS ONE"},{"issue":"7","key":"3299_CR24","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1007\/s10571-016-0456-y","volume":"37","author":"K Sangpairoj","year":"2017","unstructured":"Sangpairoj K, Vivithanaporn P, Apisawetakan S, Chongthammakun S, Sobhon P, Chaithirayanon K. RUNX1 regulates migration, invasion, and angiogenesis via p38 MAPK pathway in human glioblastoma. Cell Mol Neurobiol. 2017;37(7):1243\u201355.","journal-title":"Cell Mol Neurobiol"},{"key":"3299_CR25","doi-asserted-by":"publisher","first-page":"104839","DOI":"10.1016\/j.tiv.2020.104839","volume":"66","author":"FP Mesquita","year":"2020","unstructured":"Mesquita FP, Moreira-Nunes CA, da Silva EL, Lima LB, Daniel JP, Zuerker WJ, et al. MAPK14 (p38\u03b1) inhibition effects against metastatic gastric cancer cells: A potential biomarker and pharmacological target. Toxicol In Vitro. 2020;66:104839.","journal-title":"Toxicol In Vitro"},{"issue":"7","key":"3299_CR26","doi-asserted-by":"publisher","first-page":"e002319","DOI":"10.1136\/jitc-2020-002319","volume":"9","author":"D Baumann","year":"2021","unstructured":"Baumann D, Drebant J, H\u00e4gele T, Burger L, Serger C, Lauenstein C, et al. p38 MAPK signaling in M1 macrophages results in selective elimination of M2 macrophages by MEK inhibition. J Immunother Cancer. 2021;9(7):e002319.","journal-title":"J Immunother Cancer"},{"key":"3299_CR27","doi-asserted-by":"crossref","unstructured":"Rabia E, Garambois V, Hubert J, Bruciamacchie M, Pirot N, Delpech H, et al. editors. Anti-tumoral activity of the Pan-HER (Sym013) antibody mixture in gemcitabine-resistant pancreatic cancer models. Taylor & Francis; 2021. MAbs.","DOI":"10.1080\/19420862.2021.1914883"},{"issue":"1","key":"3299_CR28","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1186\/s12885-018-4712-z","volume":"18","author":"D Tosi","year":"2018","unstructured":"Tosi D, P\u00e9rez-Gracia E, Atis S, Vi\u00e9 N, Comb\u00e8s E, Gabanou M, et al. Rational development of synergistic combinations of chemotherapy and molecular targeted agents for colorectal cancer treatment. BMC Cancer. 2018;18(1):812.","journal-title":"BMC Cancer"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-026-03299-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-026-03299-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-026-03299-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T22:51:51Z","timestamp":1782859911000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-026-03299-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":28,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["3299"],"URL":"https:\/\/doi.org\/10.1007\/s12032-026-03299-2","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,3]]},"assertion":[{"value":"8 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Biosafety committee of Amity University.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}],"article-number":"191"}}